Alumis (NASDAQ:ALMS) CFO Sells 3,282 Shares of Stock

Alumis Inc. (NASDAQ:ALMS – Get Free Report) CFO John Schroer sold 3,282 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $86,546.34. Following the sale, the chief financial officer owned 24,718 shares of the company’s stock, valued at approximately $651,813.66. This represents a 11.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Alumis Price Performance

NASDAQ:ALMS remained flat at $27.12 during mid-day trading on Wednesday. The company had a trading volume of 629,130 shares, compared to its average volume of 2,037,268. The firm’s 50-day moving average is $25.26 and its 200 day moving average is $25.20. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -13.70 and a beta of -0.69. Alumis Inc. has a 52 week low of $3.76 and a 52 week high of $31.35.

Get Alumis alerts:

Alumis (NASDAQ:ALMS – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. On average, research analysts expect that Alumis Inc. will post -2.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on ALMS. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright reaffirmed a “neutral” rating and set a $25.00 price objective on shares of Alumis in a research report on Monday. Guggenheim upped their target price on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Morgan Stanley reissued an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research report on Friday, May 15th. Finally, Chardan Capital raised their target price on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $40.30.

View Our Latest Research Report on Alumis

Institutional Trading of Alumis

Hedge funds have recently made changes to their positions in the stock. KBC Group NV bought a new position in Alumis during the 1st quarter valued at approximately $42,000. Strs Ohio boosted its holdings in Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares in the last quarter. State of Wyoming purchased a new stake in shares of Alumis in the first quarter worth $57,000. EverSource Wealth Advisors LLC grew its stake in shares of Alumis by 600.4% in the first quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock worth $69,000 after acquiring an additional 2,684 shares during the last quarter. Finally, Assetmark Inc. bought a new position in shares of Alumis during the first quarter valued at $92,000.

About Alumis

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

See Also

• Five stocks we like better than Alumis
• SpaceX: Love the Company, But the Stock Is a Harder Call
• Ulta’s Growth Is Real, But So Are the Risks
• BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
• Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth

Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.